Siemens Healthineers Pushes Innovation in Cancer Therapy and AI Cardiology, but Stock Remains Near Lows

Despite a major U.S. government grant for next-gen cancer therapy and a strong AI cardiology showcase, Siemens Healthineers stock remains near 52-week lows amid Diagnostics weakness and a cautious market.

Two distinct strategic narratives emerged from Siemens Healthineers last week: a major grant from a U.S. government agency for a next-generation cancer treatment, and a high-profile presence at a major cardiology conference in Paris. Yet neither development has managed to budge the stock from its precarious position near multi-year troughs, where it closed at €34.51 on Friday — just 3.5% above the 52-week low of €33.34 hit the prior week.

The U.S. Advanced Research Projects Agency for Health (ARPA-H) has committed up to $83 million to fund the development of photon?flash radiation therapy, a technique that delivers ultra-short, high-intensity pulses of radiation to tumors. The goal is to spare healthy tissue while making treatment more efficient. Siemens Healthineers will contribute $23 million of that total as a cost share. The technology is still in the research phase — clinical approval and widespread adoption remain years away — but the backing from ARPA?H signals a vote of confidence in the approach. For the company, it strengthens its position in precision therapy, a segment with high entry barriers and growing demand.

A day earlier, at the EuroPCR congress in Paris from May 19 to 22, Siemens Healthineers showcased a sweeping portfolio of AI-powered cardiovascular tools under the banner “Entering a new era of AI?powered Cardiovascular Care.” Among the highlights were CT?guided PCI, the new ARTIS system, photon?counting CT systems from the NAEOTOM Alpha line, the AcuNav Lumos 4D ICE catheter, and the ACUSON Origin ultrasound system. Symposia and meet?the?expert sessions complemented the launch. The company did not disclose order figures or margin contributions, leaving investors to gauge how quickly these tools will translate into bookings.

The product push comes against a backdrop of uneven financial performance. In its second fiscal quarter, Siemens Healthineers posted comparable revenue growth of 6.1% in Imaging, with an adjusted EBIT margin of 22.4%. Precision Therapy grew 4.7% organically, achieving a 13.3% margin. But the Diagnostics unit, which has been under pressure in China and from rising inflation, posted a 6.5% comparable sales decline and a razor?thin adjusted EBIT margin of just 0.9%. Those headwinds prompted the company to adjust its fiscal 2026 outlook: it now expects comparable revenue expansion of 4.5% to 5.0% and adjusted diluted earnings per share of €2.20 to €2.30.

The stock’s technical picture underscores the market’s caution. At €34.51, the shares sit roughly 28% below their 52?week high and about 19% below the 200?day moving average of €42.65. The seven?session recovery of 3.5% suggests a tentative attempt to form a base, but the structural downtrend remains intact. With the Diagnostics drag likely to persist and the flash?therapy payoff years away, investors are left weighing near?term operational resilience against longer?term strategic bets. The fresh cardiology narrative from Paris may be the most tangible near?term catalyst — but it will take hard order data from the current quarter to turn interest into conviction.